Clinical Trial Update: Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial assessing MLN9708 as maintenance therapy after allogeneic stem cell transplant in multiple myeloma; study completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• MLN9708 (ixazomib)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2020-02-27